In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Palatin Technologies (PTN – Research Report), with a price target of $5.00. The company's shares closed last Thursday at $0.39, close to its 52-week low of $0.33. According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.7% and a 21.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Palatin Technologies is a Moderate Buy with an average price target of $5.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-palatin-technologies-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral